Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis

How Frequently Should We Screen for Hepatitis C in US Hemodialysis Centers? Evaluating the Cost-Effectiveness of Different Strategies

“…4 The likelihood of developing cirrhosis from HCV infection is low, and the progression is relatively slow-only 10%-20% of patients develop cirrhosis over 20-30 years of HCV infection, well over the average life span of patients on hemodialysis. 5 In addition, the extremely high treatment costs for HCV and cirrhosis create a dilemma for policymakers and key stakeholders 6 who must evaluate whether the cost of a stringent HCV screening strategy yields sufficient value from identifying HCV cases and outbreaks.…”